{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:05:06Z","timestamp":1783127106256,"version":"3.54.6"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.mayocp.2024.09.031","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:03:16Z","timestamp":1746086596000},"page":"868-881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pretreatment With P2Y12 Inhibitors in Contemporary Practice"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9750-746X","authenticated-orcid":false,"given":"Mandeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9038","key":"10.1016\/j.mayocp.2024.09.031_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.mayocp.2024.09.031_bib2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2024.09.031_bib3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2024.09.031_bib4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.mayocp.2024.09.031_bib5","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2024.09.031_bib6","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Writing Committee","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"38","key":"10.1016\/j.mayocp.2024.09.031_bib7","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.mayocp.2024.09.031_bib8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non\u2013ST-segment elevation acute coronary syndromes","volume":"369","author":"Montalescot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2024.09.031_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijcard.2017.09.182","article-title":"Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative","volume":"249","author":"Agewall","year":"2017","journal-title":"Int J Cardiol"},{"issue":"18","key":"10.1016\/j.mayocp.2024.09.031_bib10","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1161\/CIR.0000000000000670","article-title":"Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association","volume":"139","author":"Tamis-Holland","year":"2019","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.mayocp.2024.09.031_bib11","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2024.09.031_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/heartjnl-2012-302717","article-title":"Prevalence, indications and appropriateness of antiplatelet therapy in patients operated for acute aortic dissection: associations with bleeding complications and mortality","volume":"99","author":"Hansson","year":"2013","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.mayocp.2024.09.031_bib13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ahj.2015.06.011","volume":"170","author":"Clemmensen","year":"2015","journal-title":"Am Heart J"},{"issue":"21","key":"10.1016\/j.mayocp.2024.09.031_bib14","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2013.05.099","article-title":"Cardiovascular care facts: a report from the national cardiovascular data registry: 2011","volume":"62","author":"Masoudi","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.mayocp.2024.09.031_bib15","article-title":"Precatheterization use of P2Y12 inhibitors in non\u2013ST-elevation myocardial infarction patients undergoing early cardiac catheterization and in-hospital coronary artery bypass grafting: insights from the National Cardiovascular Data Registry","volume":"6","author":"Badri","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.mayocp.2024.09.031_bib16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jacc.2010.05.008","article-title":"Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention","volume":"56","author":"Roe","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9281","key":"10.1016\/j.mayocp.2024.09.031_bib17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.mayocp.2024.09.031_bib18","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes","volume":"381","author":"Schupke","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.mayocp.2024.09.031_bib19","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.mayocp.2024.09.031_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacc.2010.01.067","volume":"56","author":"Di Sciascio","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2024.09.031_bib23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2005.10.047","article-title":"Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention","volume":"47","author":"Steinhubl","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.mayocp.2024.09.031_bib24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehn169","article-title":"Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8","volume":"29","author":"Widimsky","year":"2008","journal-title":"Eur Heart J"},{"issue":"21","key":"10.1016\/j.mayocp.2024.09.031_bib22","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.jacc.2020.08.053","article-title":"Timing of oral P2Y12 inhibitor administration in patients with non\u2013ST-segment elevation acute coronary syndrome","volume":"76","author":"Tarantini","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2024.09.031_bib25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/14656566.2011.550573","article-title":"Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor","volume":"12","author":"Giorgi","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.mayocp.2024.09.031_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18735","article-title":"Association of pretreatment with P2Y12 receptor antagonists preceding percutaneous coronary intervention in non\u2013ST-segment elevation acute coronary syndromes with outcomes","volume":"3","author":"Dworeck","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"31","key":"10.1016\/j.mayocp.2024.09.031_bib26","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/eurheartj\/ehab277","article-title":"Debate: prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy","volume":"42","author":"Crea","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocp.2024.09.031_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijcard.2016.11.226","article-title":"Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy","volume":"229","author":"Nairooz","year":"2017","journal-title":"Int J Cardiol"},{"issue":"23","key":"10.1016\/j.mayocp.2024.09.031_bib27","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1001\/jama.2012.50788","article-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"308","author":"Bellemain-Appaix","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.mayocp.2024.09.031_bib28","article-title":"Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis","volume":"349","author":"Bellemain-Appaix","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.mayocp.2024.09.031_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archinte.1992.00400140061014","article-title":"Identification of severe coronary artery disease using simple clinical parameters","volume":"152","author":"Hubbard","year":"1992","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.mayocp.2024.09.031_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jacc.2021.11.052","article-title":"Predictors of left main coronary artery disease in the ISCHEMIA Trial","volume":"79","author":"Senior","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2024.09.031_bib32","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","article-title":"Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial","volume":"110","author":"Fox","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mayocp.2024.09.031_bib33","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jtcvs.2020.03.118","article-title":"Preoperative clopidogrel and outcomes in patients with acute coronary syndrome undergoing coronary artery bypass surgery","volume":"163","author":"Qu","year":"2022","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"17","key":"10.1016\/j.mayocp.2024.09.031_bib34","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study","volume":"67","author":"Rollini","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2024.09.031_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.mayocp.2024.09.031_bib36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ehjcvp\/pvac026","article-title":"Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"8","author":"Zhao","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"10.1016\/j.mayocp.2024.09.031_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13543784.2020.1764533","article-title":"Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development","volume":"29","author":"Milluzzo","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.mayocp.2024.09.031_bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1305978","article-title":"Platelet inhibition with cangrelor during PCI","volume":"369","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2024.09.031_bib39","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous platelet blockade with cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2024.09.031_bib40","article-title":"Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine","volume":"8","author":"Brown","year":"2018","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.mayocp.2024.09.031_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/195456","article-title":"P2Y12 receptor inhibitors in acute coronary syndromes: what is new on the horizon?","volume":"2013","author":"Oprea","year":"2013","journal-title":"Cardiol Res Pract"},{"issue":"21","key":"10.1016\/j.mayocp.2024.09.031_bib42","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.jacc.2020.09.586","article-title":"Ticagrelor or prasugrel for platelet inhibition in acute coronary syndrome patients: the ISAR-REACT 5 trial","volume":"76","author":"Mayer","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.mayocp.2024.09.031_bib43","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2024.09.031_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005528","article-title":"No benefit of ticagrelor pretreatment compared with treatment during percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"11","author":"Koul","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.mayocp.2024.09.031_bib45","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.8585","article-title":"Assessing the clinical treatment dynamics of antiplatelet therapy following acute coronary syndrome and percutaneous coronary intervention in the US","volume":"6","author":"Wang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"31","key":"10.1016\/j.mayocp.2024.09.031_bib46","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"issue":"10073","key":"10.1016\/j.mayocp.2024.09.031_bib47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2024.09.031_bib48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.mayocp.2024.09.031_bib49","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jcin.2020.01.231","article-title":"Optimal timing of intervention in NSTE-ACS without pre-treatment: the EARLY randomized trial","volume":"13","author":"Lemesle","year":"2020","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625001144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625001144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:21:56Z","timestamp":1746087716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625001144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0025619625001144"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.09.031","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment With P2Y12 Inhibitors in Contemporary Practice","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.09.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}